Clinical Roundup Researchers decipher mechanism enabling breast cancer to metastasize to the brain January 09, 2026Vol.52 No.1
Drugs & Targets FDA grants Enhertu Breakthrough Therapy designation as post-neoadjuvant therapy for HER2+ early breast cancer January 09, 2026Vol.52 No.1
Clinical Roundup Eflornithine + lomustine extend OS for patients with recurrent IDH mutant, grade 3 astrocytoma, phase III data show December 12, 2025Vol.51 No.45
In Brief Ben Ho Park, Sara Tolaney to receive awards at 2025 San Antonio Breast Cancer Symposium December 05, 2025Vol.51 No.44
Drugs & Targets FDA approves Poherdy, first biosimilar to Perjeta, for breast cancer indication November 21, 2025Vol.51 No.43
In Brief Paige Aiello joins Breast Cancer Multidisciplinary Team at Karmanos November 07, 2025Vol.51 No.41
Clinical Roundup Enhertu reduced the risk of disease recurrence or death vs. T-DM1 in high-risk HER2+ early breast cancer following neoadjuvant therapy October 24, 2025Vol.51 No.39
Clinical Roundup Enhertu + THP before surgery resulted in a pathologic complete response in high-risk HER2+ early-stage breast cancer October 24, 2025Vol.51 No.39
Clinical Roundup Verzenio delivers OS benefit in high-risk early breast cancer October 24, 2025Vol.51 No.39
